RxDoctor Payments Data

Jennifer Wo, MD

Radiation Oncology · Boston, MANPI 1306041835

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 1 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Every reported general payment came from a single manufacturer, AstraZeneca. That places this record below the midpoint for radiation oncology clinicians in MA, where the typical reported total is $145.

$135in general payments, 2019–2025

Across 1 payment — averaging $135.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$135
$505,630in research payments, 2019–2025

Across 14 payments — averaging $36,116 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$506K

What the payments were for

  • Food & beverage$135100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca1$135

How this compares

$135 in reported general payments places this provider in the 45th percentile of 200 radiation oncology providers in Massachusetts.

See all radiation oncology providers in Massachusetts

Medicare billing

Part B allowed, 2024
$192,713
Medicare patients
246
Services billed
1,953

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other radiation oncology in Boston

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →